SEARCH

SEARCH BY CITATION

References

  • Akhmanova A, Hoogenraad CC (2005). Microtubule plus-end-tracking proteins: mechanisms and functions. Curr Opin Cell Biol 17: 4754.
  • Arora S, Wang XI, Keenan SM, Andaya C, Zhang Q, Peng Y et al. (2009). Novel microtubule polymerization inhibitor with potent antiproliferative and antitumor activity. Cancer Res 69: 19101915.
  • Calligaris D, Verdier-Pinard P, Devred F, Villard C, Braguer D, Lafitte D (2010). Microtubule targeting agents: from biophysics to proteomics. Cell Mol Life Sci 67: 10891104.
  • Coquelle FM, Vitre B, Arnal I (2009). Structural basis of EB1 effects on microtubule dynamics. Biochem Soc Trans 37 (Pt 5): 9971001.
  • De Rycker M, Rigoreau L, Dowding S, Parker PJ (2009). A high-content, cell-based screen identifies micropolyin, a new inhibitor of microtubule dynamics. Chem Biol Drug Des 73: 599610.
  • Dumontet C, Duran GE, Steger KA, Beketic-Oreskovic L, Sikic BI (1996). Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). Cancer Res 56: 10911097.
  • Echalier A, Bettayeb K, Ferandin Y, Lozach O, Clement M, Valette A et al. (2008). Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex. J Med Chem 51: 737751.
  • Escuin D, Kline ER, Giannakakou P (2005). Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function. Cancer Res 65: 90219028.
  • Fojo T, Menefee M (2007). Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents. Ann Oncol 18 (Suppl. 5): v3v8.
  • Gasparini G (2001). Metronomic scheduling: the future of chemotherapy? Lancet Oncol 2: 733740.
  • Harker WG, Sikic BI (1985). Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA. Cancer Res 45: 40914096.
  • Holmfeldt P, Sellin ME, Gullberg M (2009). Predominant regulators of tubulin monomer-polymer partitioning and their implication for cell polarization. Cell Mol Life Sci 66: 32633276.
  • Hong S, Kim J, Seo JH, Jung KH, Hong SS (2012). Design, synthesis, and evaluation of 3,5-disubstituted 7-azaindoles as trk inhibitors with anticancer and antiangiogenic activities. J Med Chem 55: 53375349.
  • Honore S, Braguer D (2011). Investigating microtubule dynamic instability using microtubule-targeting agents. Methods Mol Biol 777: 245260.
  • Honore S, Pasquier E, Braguer D (2005). Understanding microtubule dynamics for improved cancer therapy. Cell Mol Life Sci 62: 30393056.
  • Honore S, Pagano A, Gauthier G, Bourgarel-Rey V, Verdier-Pinard P, Civiletti K et al. (2008). Antiangiogenic vinflunine affects EB1 localization and microtubule targeting to adhesion sites. Mol Cancer Ther 7: 20802089.
  • Jordan MA, Kamath K (2007). How do microtubule-targeted drugs work? An overview. Curr Cancer Drug Targets 7: 730742.
  • Kasibhatla S, Baichwal V, Cai SX, Roth B, Skvortsova I, Skvortsov S et al. (2007). MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps. Cancer Res 67: 58655871.
  • Kavallaris M (2010). Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 10: 194204.
  • Kavallaris M, Kuo DY, Burkhart CA, Regl DL, Norris MD, Haber M et al. (1997). Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 100: 12821293.
  • Lafanechere L (2008). Chemogenomics and cancer chemotherapy: cell-based assays to screen for small molecules that impair microtubule dynamics. Comb Chem High Throughput Screen 11: 617623.
  • Lafanechere L, Job D (2000). The third tubulin pool. Neurochem Res 25: 1118.
  • Lafanechere L, Courtay-Cahen C, Kawakami T, Jacrot M, Rudiger M, Wehland J et al. (1998). Suppression of tubulin tyrosine ligase during tumor growth. J Cell Sci 111 (Pt 2): 171181.
  • Merchan JR, Jayaram DR, Supko JG, He X, Bubley GJ, Sukhatme VP (2005). Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition. Int J Cancer 113: 490498.
  • Nguyen CH, Bisagni E, Lhoste JM (1986). Synthèse des dérivés N-5 substitués des 5H-pyrido [4,3-b] benzo [f] indoles, isomères des 6H-pyrido [4,3-b] carbazoles (ellipticines). Can J Chem 64: 454551.
  • Nguyen TL, McGrath C, Hermone AR, Burnett JC, Zaharevitz DW, Day BW et al. (2005). A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approach. J Med Chem 48: 61076116.
  • Nien CY, Chen YC, Kuo CC, Hsieh HP, Chang CY, Wu JS et al. (2010). 5-Amino-2-aroylquinolines as highly potent tubulin polymerization inhibitors. J Med Chem 53: 23092313.
  • Pasquier E, Honore S, Pourroy B, Jordan MA, Lehmann M, Briand C et al. (2005). Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells. Cancer Res 65: 24332440.
  • Peris L, Thery M, Faure J, Saoudi Y, Lafanechere L, Chilton JK et al. (2006). Tubulin tyrosination is a major factor affecting the recruitment of CAP-Gly proteins at microtubule plus ends. J Cell Biol 174: 839849.
  • Pourroy B, Honore S, Pasquier E, Bourgarel-Rey V, Kruczynski A, Briand C et al. (2006). Antiangiogenic concentrations of vinflunine increase the interphase microtubule dynamics and decrease the motility of endothelial cells. Cancer Res 66: 32563263.
  • Prise VE, Honess DJ, Stratford MR, Wilson J, Tozer GM (2002). The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses. Int J Oncol 21: 717726.
  • Small JV, Kaverina I (2003). Microtubules meet substrate adhesions to arrange cell polarity. Curr Opin Cell Biol 15: 4047.
  • Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM (2006). Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5: 219234.
  • Tozer GM, Prise VE, Wilson J, Cemazar M, Shan S, Dewhirst MW et al. (2001). Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res 61: 64136422.
  • Tozer GM, Kanthou C, Baguley BC (2005). Disrupting tumour blood vessels. Nat Rev Cancer 5: 423435.
  • Vacca A, Ribatti D, Presta M, Minischetti M, Iurlaro M, Ria R et al. (1999). Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 93: 30643073.
  • Vassal E, Barette C, Fonrose X, Dupont R, Sans-Soleilhac E, Lafanechere L (2006). Miniaturization and validation of a sensitive multiparametric cell-based assay for the concomitant detection of microtubule-destabilizing and microtubule-stabilizing agents. J Biomol Screen 11: 377389.